Ganstigmine

DB06525ExperimentalSmall molecule

Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.

Mechanism: Pharmacologically active on Acetylcholinesterase
Curator reviewed
Primary indication: Investigated for use/treatment in alzheimer's disease.Curator reviewed
Formula / weight: C₂₂H₂₇N₃O₃ · 381.476 g/mol (avg)

Resolves to

Compound

UNIIQRR9SV89XICAS457075-21-7ChEMBLCHEMBL121810

Structure

InChIKeyZOBDWFRKFSPCRB-UNMCSNQZSA-NSMILESCCC1=C(NC(=O)OC2=CC3=C(C=C2)N(C)[C@H]2ON(C)CC[C@@]32C)C=CC=C1

Targets

P22303ACHEP06276BCHE

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ganstigmine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account